Oestrogen receptor-positive, human epidermal growth factor receptor 2 (HER-2) negative breast cancer patients were randomised to be either in the control arm receiving the standard care (ie, chemotherapy and endocrine therapy) or in the treatment arm receiving the marker-guided therapy (ie, endocrine therapy). The gene discussed is ERBB2; the disease is breast carcinoma.